HRP20110726T2 - Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti - Google Patents

Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti Download PDF

Info

Publication number
HRP20110726T2
HRP20110726T2 HRP20110726TT HRP20110726T HRP20110726T2 HR P20110726 T2 HRP20110726 T2 HR P20110726T2 HR P20110726T T HRP20110726T T HR P20110726TT HR P20110726 T HRP20110726 T HR P20110726T HR P20110726 T2 HRP20110726 T2 HR P20110726T2
Authority
HR
Croatia
Prior art keywords
benzo
image
group
dihydro
dioxynyl
Prior art date
Application number
HRP20110726TT
Other languages
English (en)
Inventor
Virginia L. Smith-Swintosky
Allen B. Reitz
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20110726T1 publication Critical patent/HRP20110726T1/hr
Publication of HRP20110726T2 publication Critical patent/HRP20110726T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Claims (10)

1. Spoj formule (I): [image] ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; [image] je odabran iz skupine koju sačinjavaju [image] [image] [image] [image] pri čemu b je cijeli broj od 0 do 4; i gdje c je cijeli broj od 0 do 2; svaki R5 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada [image] ili [image] tada a je 1.
2. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; [image] je odabran iz skupine koju sačinjavaju [image] [image] [image] i [image] gdje b je cijeli broj od 0 do 2; i gdje c je cijeli broj od 0 do 1; svaki R5 je Nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada [image] ili [image] tada a je 1.
3. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; [image] je odabran iz skupine koju sačinjavaju [image] [image] [image] pri čemu b je cijeli broj od 0 do 2; i pri čemu c je 0; svaki R5 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika pod uvjetom da kada [image] tada a je 1.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 3 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i metil; a je cijeli broj od 1 do 2: [image] je odabran iz skupine koju sačinjavaju 2-(2,3-dihidrobenzo[1,4]dioksinil), 2-(benzo[1,3]dioksolil), 2-(3,4-dihidro-2H-benzo[1,4]dioksepinil), 2-(6-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-fluoro-2,3-dihidro-benzo[1,4]dioksinil), 2-(kromanil), 2-(5-fluoro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-kloro-benzo[1,3]dioksolil), 2-(7-metil-2,3-dihidro-benzo[1,4]dioksinil), 2-(5-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-bromo-2,3-dihidro-benzo[1,4]dioksinil), 2-(6,7-dikloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(8-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(2,3-dihidro-nafto[2,3-b][1,4]dioksinil) i 2-(4-metil-benzo[1,3]dioksolil); pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada [image] je 2-(3,4-dihidro-2H-benzo[1,4]dioksepinil), tada a je 1.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 4 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i metil; R4 je odabran iz skupine koja sadrži vodik i metil; a je cijeli broj od 1 do 2; [image] je odabran iz skupine koju sačinjavaju 2-benzo[1,3]dioksolil), 2-(2,3-dihidro-benzo[1,4]dioksinil), 2-(6-kloro-2,3- dihidro-benzo[1,4]dioksinil), 2-(7-kloro-2,3-dihidro-benzo[1,4]dioksinil), 2-(7-metil-2,3-dihidro-benzo[1,4]dioksinil), 2-(6-bromo-2,3-dihidrobenzo[1,4]dioksinil) i 2-(6,7-dikloro-2,3-dihidro-benzo[1,4]dioksinil).
6. Spoj prema zahtjevu 1, naznačen time da je spoj prema formuli (I) odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidrobenzo[1,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli.
7. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod liječenja pretilosti.
8. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod poticanja gubitka težine.
9. Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro-benzol[1,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod suzbijanja apetita.
10. Spoj formule (II) [image] ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita.
HRP20110726TT 2005-12-19 2011-10-07 Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti HRP20110726T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75149905P 2005-12-19 2005-12-19
US11/611,938 US8492431B2 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
PCT/US2006/048681 WO2007075833A2 (en) 2005-12-19 2006-12-19 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity

Publications (2)

Publication Number Publication Date
HRP20110726T1 HRP20110726T1 (hr) 2011-12-31
HRP20110726T2 true HRP20110726T2 (hr) 2013-02-28

Family

ID=37992995

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20110726TT HRP20110726T2 (hr) 2005-12-19 2011-10-07 Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti

Country Status (31)

Country Link
US (1) US8492431B2 (hr)
EP (1) EP1968574B9 (hr)
JP (1) JP5190378B2 (hr)
KR (1) KR101363308B1 (hr)
CN (1) CN101365442B (hr)
AR (1) AR058389A1 (hr)
AT (1) ATE519484T1 (hr)
AU (1) AU2006331637B2 (hr)
BR (1) BRPI0620019A2 (hr)
CA (1) CA2634093C (hr)
CR (1) CR10164A (hr)
CY (1) CY1112357T1 (hr)
DK (1) DK1968574T3 (hr)
EA (1) EA016560B1 (hr)
ES (1) ES2369761T3 (hr)
HK (1) HK1124540A1 (hr)
HR (1) HRP20110726T2 (hr)
IL (1) IL192107A (hr)
ME (1) ME01344B (hr)
MY (1) MY145823A (hr)
NO (1) NO20083006L (hr)
NZ (1) NZ568960A (hr)
PE (1) PE20070813A1 (hr)
PL (1) PL1968574T3 (hr)
PT (1) PT1968574E (hr)
RS (1) RS52044B (hr)
SI (1) SI1968574T1 (hr)
SV (1) SV2008002952A (hr)
UY (1) UY30033A1 (hr)
WO (1) WO2007075833A2 (hr)
ZA (1) ZA200806279B (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006127184A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
JP5514804B2 (ja) 2008-04-29 2014-06-04 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2009133110A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
EP2340246A2 (en) 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2850513A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
CA2850015A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Improved process for the preparation of sulfamide derivatives

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (hr) * 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2179733C (en) 1993-12-23 2007-03-27 Michael J. Costanzo Anticonvulsant pseudofructopyranose sulfamates
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
DE69614835T2 (de) * 1995-02-15 2002-04-25 Annovis Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1997019919A1 (fr) 1995-11-30 1997-06-05 C & C Research Laboratories Derives de sulfamides
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
WO1998000130A2 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant sulfamate derivatives useful in treating obesity
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
AP1055A (en) 1996-08-14 2002-04-04 Searle & Co Crysttalline form of 4-[5-methyl-3-phenylisoxazol-4-YI] benzenesulfonamide.
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
EP1014959B1 (en) * 1997-08-15 2004-10-20 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DK72798A (da) 1998-05-28 1998-05-28 Novo Nordisk As Treatment of GABA-uptake related disorders
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
DK1143967T3 (da) * 1999-01-19 2005-01-10 Ortho Mcneil Pharm Inc Anticonvulsive derivater egnede til behandling af Hortons hovedpine
AR022321A1 (es) 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
HUP0200469A3 (en) 1999-02-24 2003-03-28 Univ Cincinnati Cincinnati Use of sulfamate derivatives for treating impulse control disorders
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
JP2003521471A (ja) * 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
WO2000061137A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
WO2000061140A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
CA2372806A1 (en) 1999-05-04 2000-11-09 Keith R. Edwards Intravenous valproate for acute treatment of migraine headache
CA2686633A1 (en) 1999-06-14 2000-12-21 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
AU782759B2 (en) * 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
EP1309324B1 (en) * 2000-07-07 2006-03-22 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
JP2004505043A (ja) * 2000-08-02 2004-02-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド うつ病の治療で用いるに有用な抗痙攣性誘導体
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2002096424A1 (en) 2001-05-25 2002-12-05 Queen's University At Kingston Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
EP1631542A1 (en) 2003-04-10 2006-03-08 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
WO2004098584A1 (en) 2003-04-16 2004-11-18 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2004093912A1 (ja) 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1776106B1 (en) 2004-06-22 2013-08-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
PE20061335A1 (es) * 2005-04-22 2006-12-29 Wyeth Corp Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
WO2006127184A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2008061903A1 (en) * 2006-11-22 2008-05-29 Agfa Healthcate Inc. Method and system for client / server distributed image processing
EP2238122A1 (en) * 2008-01-07 2010-10-13 Janssen Pharmaceutica, N.V. Preparation of sulfamide derivatives
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2340246A2 (en) * 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide

Also Published As

Publication number Publication date
ES2369761T3 (es) 2011-12-05
EP1968574B9 (en) 2012-05-09
AU2006331637A1 (en) 2007-07-05
NZ568960A (en) 2011-04-29
WO2007075833A2 (en) 2007-07-05
CN101365442A (zh) 2009-02-11
PL1968574T3 (pl) 2012-01-31
KR101363308B1 (ko) 2014-02-18
US8492431B2 (en) 2013-07-23
NO20083006L (no) 2008-09-11
CA2634093A1 (en) 2007-07-05
CY1112357T1 (el) 2015-12-09
IL192107A (en) 2014-05-28
UY30033A1 (es) 2007-03-30
EA016560B1 (ru) 2012-05-30
DK1968574T3 (da) 2011-11-21
EP1968574B1 (en) 2011-08-10
AU2006331637B2 (en) 2013-01-10
SI1968574T1 (sl) 2011-12-30
KR20080089409A (ko) 2008-10-06
HRP20110726T1 (hr) 2011-12-31
PT1968574E (pt) 2011-10-12
MY145823A (en) 2012-04-30
ME01344B (me) 2013-12-20
JP2009520036A (ja) 2009-05-21
CA2634093C (en) 2014-08-05
SV2008002952A (es) 2010-01-18
ZA200806279B (en) 2009-10-28
PE20070813A1 (es) 2007-08-13
JP5190378B2 (ja) 2013-04-24
RS52044B (en) 2012-04-30
BRPI0620019A2 (pt) 2011-10-25
CN101365442B (zh) 2011-11-16
US20080027131A1 (en) 2008-01-31
EA200870093A1 (ru) 2009-02-27
AR058389A1 (es) 2008-01-30
IL192107A0 (en) 2009-08-03
EP1968574A2 (en) 2008-09-17
CR10164A (es) 2009-01-14
HK1124540A1 (en) 2009-07-17
ATE519484T1 (de) 2011-08-15
WO2007075833A3 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
HRP20110726T2 (hr) Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti
HRP20110384T1 (hr) Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja
HRP20100007T1 (hr) Upotreba benzo-spojenih heterocikličkih derivata sulfamida za liječenje boli
HRP20120018T1 (hr) Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida kao neurozaštitnih sredstava
HRP20110008T1 (hr) Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za smanjenje razine masnoća i šećera u krvi
JP2009520036A5 (hr)
CA2570606A1 (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2009520035A5 (hr)
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
Agrawal Pharmacological activities of flavonoids: a review
TW200716595A (en) Chromane and chromene derivatives and uses thereof
BR0116624A (pt) Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
PL2176252T3 (pl) 2,3-dihydrobenzo[1,4]dioksyn-2-ylometylopochodne jako antagoniści receptora alfa2c do zastosowania w leczeniu chorób obwodowego i ośrodkowego układu nerwowego
AR110945A1 (es) Suplemento de alimento para animales y composición que comprende dicho suplemento
JP2012522030A5 (hr)
JP2005518381A5 (hr)
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
BRPI0915890A2 (pt) forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
AR053790A1 (es) Acidos biariloximetilarencarboxilicos. procesos de obtencion y composiciones farmaceuticas.
AR064982A1 (es) Concentrado de suspension oleosa con principios activos agroquimicos microencapulados
AR104121A1 (es) DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA
CA2431079A1 (en) Method and composition for the treatment of diabetic neuropathy
Zhang et al. The role of flavonoids in the osteogenic differentiation of mesenchymal stem cells
AR086625A1 (es) Combinacion farmaceutica sinergica para el tratamiento del carcinoma de celula escamosa
RU2013146602A (ru) Фармацевтическая композиция для лечения болезни печени